Imidazoline receptors. Historic review and current status of knowledge.
Autor(a) principal: | |
---|---|
Data de Publicação: | 1993 |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3166 |
Resumo: | After the initial demonstration, by Ruffolo in 1977, that imidazolines and phenethylamines do not interact in the same manner with adrenoceptors, a different class of receptors (imidazoline-preferring receptors) was identified. They are present in the brain stem and in several tissues at the periphery. This imidazoline-preferring receptor is believed to be the target of the anti-hypertensive effect of clonidine and the newly developed clonidine-related substances, rilmenidine and moxonidine. This review summarises the current knowledge and latest developments in this field, including the consensus on the nomenclature proposed by Ernsberger to classify the imidazoline receptors in I1 (clonidine and idazoxan sensitive) and I2 (idazoxan sensitive but clonidine insensitive) types. |
id |
RCAP_d69e13c32ac7a061e0d4cc1cb321493f |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/3166 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Imidazoline receptors. Historic review and current status of knowledge.Receptores imidazolínicos. Revisão histórica e estado actual dos conhecimentos.After the initial demonstration, by Ruffolo in 1977, that imidazolines and phenethylamines do not interact in the same manner with adrenoceptors, a different class of receptors (imidazoline-preferring receptors) was identified. They are present in the brain stem and in several tissues at the periphery. This imidazoline-preferring receptor is believed to be the target of the anti-hypertensive effect of clonidine and the newly developed clonidine-related substances, rilmenidine and moxonidine. This review summarises the current knowledge and latest developments in this field, including the consensus on the nomenclature proposed by Ernsberger to classify the imidazoline receptors in I1 (clonidine and idazoxan sensitive) and I2 (idazoxan sensitive but clonidine insensitive) types.After the initial demonstration, by Ruffolo in 1977, that imidazolines and phenethylamines do not interact in the same manner with adrenoceptors, a different class of receptors (imidazoline-preferring receptors) was identified. They are present in the brain stem and in several tissues at the periphery. This imidazoline-preferring receptor is believed to be the target of the anti-hypertensive effect of clonidine and the newly developed clonidine-related substances, rilmenidine and moxonidine. This review summarises the current knowledge and latest developments in this field, including the consensus on the nomenclature proposed by Ernsberger to classify the imidazoline receptors in I1 (clonidine and idazoxan sensitive) and I2 (idazoxan sensitive but clonidine insensitive) types.Ordem dos Médicos1993-12-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3166oai:ojs.www.actamedicaportuguesa.com:article/3166Acta Médica Portuguesa; Vol. 6 No. 12 (1993): Dezembro; 599-604Acta Médica Portuguesa; Vol. 6 N.º 12 (1993): Dezembro; 599-6041646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3166https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3166/2505Moura, Dinfo:eu-repo/semantics/openAccess2022-12-20T11:01:45Zoai:ojs.www.actamedicaportuguesa.com:article/3166Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:18:11.668004Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Imidazoline receptors. Historic review and current status of knowledge. Receptores imidazolínicos. Revisão histórica e estado actual dos conhecimentos. |
title |
Imidazoline receptors. Historic review and current status of knowledge. |
spellingShingle |
Imidazoline receptors. Historic review and current status of knowledge. Moura, D |
title_short |
Imidazoline receptors. Historic review and current status of knowledge. |
title_full |
Imidazoline receptors. Historic review and current status of knowledge. |
title_fullStr |
Imidazoline receptors. Historic review and current status of knowledge. |
title_full_unstemmed |
Imidazoline receptors. Historic review and current status of knowledge. |
title_sort |
Imidazoline receptors. Historic review and current status of knowledge. |
author |
Moura, D |
author_facet |
Moura, D |
author_role |
author |
dc.contributor.author.fl_str_mv |
Moura, D |
description |
After the initial demonstration, by Ruffolo in 1977, that imidazolines and phenethylamines do not interact in the same manner with adrenoceptors, a different class of receptors (imidazoline-preferring receptors) was identified. They are present in the brain stem and in several tissues at the periphery. This imidazoline-preferring receptor is believed to be the target of the anti-hypertensive effect of clonidine and the newly developed clonidine-related substances, rilmenidine and moxonidine. This review summarises the current knowledge and latest developments in this field, including the consensus on the nomenclature proposed by Ernsberger to classify the imidazoline receptors in I1 (clonidine and idazoxan sensitive) and I2 (idazoxan sensitive but clonidine insensitive) types. |
publishDate |
1993 |
dc.date.none.fl_str_mv |
1993-12-30 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3166 oai:ojs.www.actamedicaportuguesa.com:article/3166 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3166 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/3166 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3166 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3166/2505 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 6 No. 12 (1993): Dezembro; 599-604 Acta Médica Portuguesa; Vol. 6 N.º 12 (1993): Dezembro; 599-604 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130634201858048 |